• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . High nasopharyngeal and serum IL-6 levels and the - 573G > C polymorphism (rs1800796) are linked with the risk of severe COVID-19

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2025 Mar 5;25(1):315.
doi: 10.1186/s12879-025-10695-y. High nasopharyngeal and serum IL-6 levels and the - 573G > C polymorphism (rs1800796) are linked with the risk of severe COVID-19 in a Mexican population: a case‒control study

Kirvis Torres-Poveda[SUP] 1 2 [/SUP], Margarita Bahena-Román[SUP] 1 [/SUP], Carla O Contreras-Ochoa[SUP] 1 [/SUP], Alfredo Lagunas-Martínez[SUP] 1 [/SUP], Víctor Hugo Bermúdez-Morales[SUP] 1 [/SUP], Victoria Pando-Robles[SUP] 1 [/SUP], Esmeralda Ortiz-Flores[SUP] 1 [/SUP], Fabiola Cortés-Pedroza[SUP] 1 [/SUP], María E Santana-Román[SUP] 1 [/SUP], Cecilia Martínez-Campos[SUP] 1 3 [/SUP], Miguel Sánchez-Alemán[SUP] 1 [/SUP], Joaquin Manzo-Merino[SUP] 4 [/SUP], Ausencio Morales-Ortega[SUP] 5 [/SUP], Daniel Alberto Madrid-González[SUP] 6 [/SUP], Marco Antonio Cantú-Cuevas[SUP] 6 [/SUP], Héctor Barón-Olivares[SUP] 7 [/SUP], Vicente Madrid-Marina[SUP] 8 [/SUP]



Affiliations
Abstract

Background: COVID-19 was the leading cause of death in Mexico between 2020 and 2021. SARS-CoV-2 infection varies widely among individuals and populations. Since variations in genes related to the immune response may play a role in the susceptibility to and outcome of COVID-19, the associations of gene polymorphisms (SNPs) of IL-6 (- 573G > C, rs1800796), TNF-α (- 308G > A, rs1800629), and IFN-γ (- 1615 C > T, rs2069705) with the expression levels of these proteins in the nasopharynx and serum were evaluated in a Mexican population with mild, severe, or critical COVID-19.
Methods: A total of 560 COVID-19 patients (309 mild, 163 severe, and 88 critical cases) and 560 age- and sex-matched COVID-19-negative controls were recruited for this case‒control study. The selected SNPs were genotyped via allelic discrimination. Logistic regression analysis was conducted considering four models of inheritance, and ORs were determined for each genotypic variant, adjusting for associated comorbidities in the multivariate model. The nasopharyngeal mRNA expression levels of IL-6, IFN-γ and TNF-α were determined. The levels of IL-6, IFN-γ, IFN-α2, and TNF-α in the serum were quantified. Significant differences were assessed via the Wilcoxon Mann‒Whitney U test.
Results: The C allele of the IL-6 - 573 SNP was associated with a greater risk of mild and severe COVID-19 (OR: 2.3, CI: 1.897-2.838, p = 0.0001; and OR: 1.5, CI: 1.167-1.949, p = 0.002, respectively), whereas the A allele of the TNF-α - 308 SNP and the T allele of the IFN-γ - 1615 SNP were shown protective roles against severe COVID-19 (OR: 0.3, CI: 0.189-0.537, p = 0.0001; and OR: 0.7, CI: 0.563-1.006, p = 0.05) and against critical COVID-19 (OR: 0.3, CI: 0.158-0.640, p = 0.001; and OR: 0.4, CI: 0.290-0.678, p = 0.0001), adjusting for diabetes and hypertension. Nasopharyngeal IL-6 expression levels were lower in mild COVID-19 patients (p = 0.001) than in critical patients (p = 0.005). Serum IL-6 levels were significantly elevated in the critical cases (p = 0.01).
Conclusions: Our results revealed that the IL-6 - 573 G > C SNP and increased IL-6 nasopharyngeal and serum levels are associated with the risk of severe COVID-19 in a Mexican population.

Keywords: COVID-19; Cytokines; Genetic susceptibility; Interleukin-6; Mexico; Single nucleotide polymorphisms.

 
Back
Top Bottom